HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

IMO-2055

Also Known As:

EMD 1201081

Networked: 4 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleotides: 15763
  - Polynucleotides: 218
    - Oligonucleotides: 5145
      - IMO-2055: 4

Experts

1.	de La Bourdonnaye, Guillaume: 2 articles (04/2015 - 08/2014)
2.	Chan, Emily: 1 article (04/2015)
3.	Heiskala, Marja: 1 article (04/2015)
4.	Hwang, Jimmy: 1 article (04/2015)
5.	Kwak, Eunice L: 1 article (04/2015)
6.	Mita, Monica: 1 article (04/2015)
7.	Bexon, A: 1 article (12/2014)
8.	Csoszi, T: 1 article (12/2014)
9.	Erfan, J: 1 article (12/2014)
10.	Evans, M: 1 article (12/2014)

Related Diseases

1.	Squamous Cell Carcinoma of Head and Neck 12/01/2014 - "Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)." 12/01/2014 - "To determine whether EMD 1201081, a TLR9 agonist, added to cetuximab had antitumor activity in second-line recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). " 10/01/2013 - "This Phase Ib trial assessed the maximum tolerated dose (MTD) and safety of the Toll-like receptor 9 agonist IMO-2055 combined with 5-fluorouracil, cisplatin, and cetuximab (PFE) as first-line palliative treatment in patients with relapsed and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). " 10/01/2013 - "Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck."
2.	Colorectal Neoplasms (Colorectal Cancer) 04/01/2015 - "This phase 1b, open-label, 3 + 3 dose-escalation trial was performed to determine the recommended phase 2 dose of IMO-2055 combined with FOLFIRI/cetuximab in patients with previously treated, advanced/metastatic colorectal cancer (NCT00719199). " 04/01/2015 - "Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease."
3.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 08/01/2014 - "The objective of this phase Ib dose-escalation trial (3 + 3 design) was to determine the recommended phase II dose (RP2D) of IMO-2055 when combined with erlotinib and bevacizumab in patients with advanced non-small cell lung cancer (NSCLC). " 08/01/2014 - "Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy."
4.	Febrile Neutropenia 10/01/2013 - "Dose-limiting toxicities (DLTs; ie, any Grade [G]3/4 treatment-related adverse events [TEAEs] in cycle 1) occurred in 2/4 patients treated with IMO-2055 0.32 mg/kg (G4 hypokalemia and hypomagnesemia [n=1]; G4 septicemia, hyperthermia, febrile neutropenia, and G3 hypotension [n=1]). "
5.	Sepsis (Septicemia) 10/01/2013 - "In the IMO-2055 0.16-mg/kg expansion cohort, 1 patient experienced DLTs of G3 sepsis, bacteremia, and hyperthermia. " 10/01/2013 - "Dose-limiting toxicities (DLTs; ie, any Grade [G]3/4 treatment-related adverse events [TEAEs] in cycle 1) occurred in 2/4 patients treated with IMO-2055 0.32 mg/kg (G4 hypokalemia and hypomagnesemia [n=1]; G4 septicemia, hyperthermia, febrile neutropenia, and G3 hypotension [n=1]). "

Related Drugs and Biologics

1.	Cetuximab (Erbitux)
2.	Toll-Like Receptor 9
3.	Fluorouracil (Carac)
4.	Cisplatin (Platino)
5.	Erlotinib Hydrochloride (CP 358,774)
6.	Bevacizumab (Avastin)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Palliative Care (Palliative Therapy)
3.	Therapeutics